Form 4: Blueprint Medicines Executive Receives Stock Options and Restricted Stock Units

Debra Durso-Bumpus, Chief People Officer at Blueprint Medicines, was granted stock options and restricted stock units on March 1, 2024.

Summary

• Debra Durso-Bumpus, Chief People Officer of Blueprint Medicines Corp, received 12,500 restricted stock units and options to purchase 25,000 shares of common stock on March 1, 2024.
• The restricted stock units were granted under the company's 2015 Stock Option and Incentive Plan.
• The stock options have an exercise price of $95.12 and vest monthly starting April 1, 2024, over a four-year period, expiring on March 1, 2034.
• Following the transaction, Durso-Bumpus directly owns 62,678 shares of Blueprint Medicines common stock and options to purchase 25,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating a stable and incentivized management structure. This is generally viewed positively.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This type of equity compensation is standard practice for publicly traded companies to incentivize executives.

Comparison to Industry Standards

• Equity grants are a common component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Vertex also use stock options and restricted stock units to align executive incentives with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry norms for similar-sized companies.

Stakeholder Impact

• The equity grants align the executive's interests with those of the shareholders, potentially leading to increased shareholder value.
• The compensation package can motivate the executive to improve company performance, benefiting employees and other stakeholders.

Key Dates